Neion Bio Strengthens Genome Engineering Leadership with Appointment of Colossal Biosciences Veteran James KehlerNEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Neion Bio, a biotechnology company revolutionizing the production of biologic medicines, today announced the appointment of James Kehler, VMD, PhD, as Head of Avian Sciences. Dr. Kehler joins Neion Bio from Colossal Biosciences, where he served as Vice President of BioSynergy overseeing multiple programs at the intersection of genome engineering and animal science. His appointment further strengthens Neion’s leadership bench in advanced genome engineering, following the earlier recruitment of founding geneticist and Chief Scientific Officer Dr. Sven Bocklandt, who also joined Neion from Colossal Biosciences.
Neion Bio Emerges from Stealth with Multi-Product Biosimilar Partnership Leveraging Its Cutting-Edge Genetic Engineering PlatformNEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Neion Bio, a biotechnology company revolutionizing the production of biologic medicines, today announced its emergence from stealth and the signing of its first co-development and supply agreement with a major global pharmaceutical company. Neion’s Raptor™ platform utilizes the latest genetic engineering tools to produce recombinant biologics in eggs, enabling scalable and efficient production of virtually any therapeutic protein. This commercial deal provides Neion with near-term revenue through up-front and milestone payments, along with long-term participation through profit sharing once products are commercialized.
